NeuroAdjuvants Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

NeuroAdjuvants General Information

Description

Developer of peptide-based therapeutics intended to offer therapeutics for neurological treatment. The company's peptide-based therapeutics is produced by research and development of neuropeptide-based therapeutics for the treatment of neurological, psychiatric, metabolic and inflammatory disorders, enabling healthcare sectors to provide proper treatment for neurological diseases.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Corporate Office
  • 417 Wakara Way
  • Suite 3510
  • Salt Lake City, UT 84108
  • United States
+1 (801) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuroAdjuvants Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 29-Nov-2018 00.00 Completed Out of Business
3. Grant 26-Mar-2009 00.00 Completed Startup
2. Early Stage VC (Series A2) 27-Jun-2007 $1000K $1.2M 00.00 Completed Startup
1. Early Stage VC (Series A1) 22-Jan-2007 $200K $200K 00.00 Completed Startup
To view NeuroAdjuvants’s complete valuation and funding history, request access »

NeuroAdjuvants Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A2 000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A1 000,000 00.000000 00 00 00 00 0.000
To view NeuroAdjuvants’s complete cap table history, request access »

NeuroAdjuvants Patents

NeuroAdjuvants Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10537573-B2 Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use Active 21-Jan-2014 00000000000 000
US-20160367554-A1 Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use Active 21-Jan-2014 0000000000
CA-2858811-A1 Neuropeptide analogs, compositions, and methods for treating pain Inactive 15-Dec-2010 000000000
AU-2011343822-A1 Neuropeptide analogs, compositions, and methods for treating pain Active 15-Dec-2010 000000000
US-20130324467-A1 Neuropeptide analogs, compositions, and methods for treating pain Inactive 15-Dec-2010 A61K38/10 0
To view NeuroAdjuvants’s complete patent history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »